Sierra Oncology (SRRA) Shares Up 6.6%
Sierra Oncology Inc (NASDAQ:SRRA) shares shot up 6.6% on Tuesday . The stock traded as high as $3.15 and last traded at $3.09. 642,516 shares traded hands during mid-day trading, an increase of 76% from the average session volume of 365,398 shares. The stock had previously closed at $2.90.
Several research firms recently weighed in on SRRA. ValuEngine upgraded shares of Sierra Oncology from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. Zacks Investment Research cut shares of Sierra Oncology from a “hold” rating to a “sell” rating in a research report on Thursday, October 26th. Finally, Jefferies Group upgraded shares of Sierra Oncology from a “hold” rating to a “buy” rating in a research report on Monday, October 23rd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $4.00.
Sierra Oncology (NASDAQ:SRRA) last issued its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.03. research analysts expect that Sierra Oncology Inc will post -0.85 earnings per share for the current year.
Sierra Oncology Company Profile
Sierra Oncology, Inc, formerly ProNAi Therapeutics, Inc, is a clinical-stage drug development company. The Company’s lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response (DDR) network.
Receive News & Ratings for Sierra Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sierra Oncology and related companies with MarketBeat.com's FREE daily email newsletter.